En una paciente gestante heterocigota para factor v leiden sin abortos precios,

Thromboprophylaxis with heparin during pregnancy is generally NOT routinely recommended for a pregnant woman who is heterozygous for factor V Leiden mutation and has no history of previous pregnancy losses or personal/family history of venous thromboembolism (VTE). Current UK guidelines and international expert consensus agree that heterozygous factor V Leiden (FVL) is classified as a moderate-risk inherited thrombophilia, and the absolute risk of VTE during pregnancy in such women is relatively low (around 0.8%) in the absence of additional risk factors.

The Royal College of Obstetricians and Gynaecologists (RCOG) and other bodies advise clinical surveillance during pregnancy for heterozygous FVL mutation alone, reserving pharmacological thromboprophylaxis with low-molecular-weight heparin (LMWH) for cases where additional risk factors exist, such as a positive family history of VTE, prior thrombosis, or other significant maternal risks Rath et al. 2026 Rath et al. 2026. In particular, LMWH prophylaxis should be considered if a weighted risk assessment score exceeds thresholds indicating elevated risk, for example above 3, or from 28 weeks if the score is 2 or higher Rath et al. 2026 Rath et al. 2026. Without these additional risk factors, antenatal pharmacological prophylaxis is not routinely indicated for heterozygous FVL Rath et al. 2026 Rath et al. 2026.

Postpartum thromboprophylaxis with LMWH might be considered if a positive family history of VTE or other risk factors are present, typically continued for at least 6 weeks after delivery Rath et al. 2026 Rath et al. 2026. However, this recommendation focuses on the postpartum period rather than the antepartum phase.

NICE guidelines (NG89) on venous thromboembolism recommend thromboprophylaxis with LMWH in pregnant women only when their risk of VTE is increased, such as during hospitalization or significant immobility, but do not specifically recommend routine antepartum heparin prophylaxis for inherited thrombophilia without additional risk factors NICE NG89.

Moreover, heparin (including LMWH) does not cross the placenta and may be safely used during pregnancy when indicated, but its use requires specialist involvement and careful risk-benefit evaluation, particularly considering risks such as bleeding and reduced bone density with prolonged use SmPC Heparin,SmPC Heparin,SmPC Heparin,SmPC Heparin.

Recent observational evidence from a large case-control study suggests that LMWH prophylaxis in pregnant women with heterozygous factor V Leiden does not uniformly reduce the overall incidence of pregnancy complications when no additional risk factors or previous losses are present, and routine use may not be justified due to risks, costs, and lack of clear benefit Maglic et al. 2025. LMWH therapy was associated with improved outcomes primarily in high-risk subgroups and women with prior pregnancy complications, but not in low-risk heterozygous FVL carriers without complications Maglic et al. 2025.

In summary, for a pregnant patient heterozygous for factor V Leiden with no history of previous pregnancy losses or VTE, thromboprophylaxis with heparin during pregnancy is not routinely necessary; careful clinical surveillance and individualized risk assessment are appropriate to guide management, involving specialist input as needed NICE NG89,Rath et al. 2026 Rath et al. 2026 Maglic et al. 2025.